Finger length points to prostate cancer risk

December 01, 2010

Men who have long index fingers are at lower risk of prostate cancer, a new study published today in the British Journal of Cancer has found.

The study led by The University of Warwick and The Institute of Cancer Research (ICR) found men whose index finger is longer than their ring finger were one third less likely to develop the disease than men with the opposite finger length pattern.

"Our results show that relative finger length could be used as a simple test for prostate cancer risk, particularly in men aged under 60," Joint senior author Professor Ros Eeles from the ICR and The Royal Marsden NHS Foundation Trust says. "This exciting finding means that finger pattern could potentially be used to select at-risk men for ongoing screening, perhaps in combination with other factors such as family history or genetic testing."

Over a 15 year period from 1994 to 2009, the researchers quizzed more than 1,500 prostate cancer patients at The Royal Marsden NHS Foundation Trust in London and Surrey, Nottingham City Hospital and The Royal Hallamshire Hospitals in Sheffield, along with more than 3,000 healthy control cases. The men were shown a series of pictures of different finger length patterns and asked to identify the one most similar to their own right hand.

The most common finger length pattern, seen in more than half the men in the study, was a shorter index than ring finger. Men whose index and ring fingers were the same length (about 19 per cent) had a similar prostate cancer risk, but men whose index fingers were longer than their ring finger were 33 per cent less likely to have prostate cancer. Risk reduction was even greater in men aged under 60 years- these men were 87 per cent less likely to be in the prostate cancer group.

The relative length of index and ring fingers is set before birth, and is thought to relate to the levels of sex hormones the baby is exposed to in the womb. Less testosterone equates to a longer index finger; the researchers now believe that being exposed to less testosterone before birth helps protect against prostate cancer later in life. The phenomenon is thought to occur because the genes HOXA and HOXD control both finger length and development of sex organs.

Previous studies have found a link between exposure to hormones while in the womb and the development of other diseases, including breast cancer (linked to higher prenatal oestrogen exposure) and osteoarthritis (linked to having an index finger shorter than ring finger).

Joint senior author, Professor Ken Muir, says: "Our study indicates it is the hormone levels that babies are exposed to in the womb which can have an effect decades later. As our research continues, we will be able to look at a further range of factors that may be involved in the make-up of the disease."
-end-
The study was funded by Prostate Cancer Research Foundation and Cancer Research UK.

University of Warwick

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.